Humana Inc. $HUM Shares Acquired by Continuum Advisory LLC

Continuum Advisory LLC boosted its stake in Humana Inc. (NYSE:HUM) by 12.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,405 shares of the insurance provider’s stock after acquiring an additional 2,032 shares during the period. Continuum Advisory LLC’s holdings in Humana were worth $4,788,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in HUM. Vanguard Group Inc. increased its holdings in shares of Humana by 1.6% in the second quarter. Vanguard Group Inc. now owns 14,199,096 shares of the insurance provider’s stock valued at $3,471,395,000 after purchasing an additional 226,224 shares during the period. Dodge & Cox grew its position in Humana by 5.6% in the 2nd quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock valued at $2,775,562,000 after buying an additional 597,705 shares during the last quarter. State Street Corp increased its stake in Humana by 1.1% in the 2nd quarter. State Street Corp now owns 5,377,390 shares of the insurance provider’s stock valued at $1,319,334,000 after buying an additional 58,094 shares during the period. Pzena Investment Management LLC increased its stake in Humana by 6.5% in the 2nd quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock valued at $996,664,000 after buying an additional 247,744 shares during the period. Finally, Geode Capital Management LLC raised its position in Humana by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 3,130,829 shares of the insurance provider’s stock worth $762,233,000 after buying an additional 57,267 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

Shares of HUM stock opened at $258.50 on Tuesday. The stock has a fifty day moving average price of $258.07 and a 200 day moving average price of $260.74. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02. The stock has a market cap of $31.09 billion, a PE ratio of 24.23, a P/E/G ratio of 1.51 and a beta of 0.46. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $315.35.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.29. The company had revenue of $32.65 billion for the quarter, compared to analyst estimates of $31.99 billion. Humana had a return on equity of 12.86% and a net margin of 1.02%.Humana’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.16 earnings per share. Sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.4%. Humana’s payout ratio is presently 33.18%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a report on Tuesday, October 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a report on Wednesday, October 8th. The Goldman Sachs Group cut their target price on Humana from $235.00 to $215.00 and set a “sell” rating for the company in a research note on Monday, November 24th. KeyCorp reissued a “sector weight” rating on shares of Humana in a report on Friday, December 12th. Finally, Sanford C. Bernstein upped their price objective on Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Nine equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Humana currently has a consensus rating of “Hold” and a consensus target price of $294.32.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.